or Try an Advanced Search...

    Technical Analysis for PRME - Prime Medicine, Inc.

    Grade Last Price % Change Price Change
    F 5.36 -3.77% -0.21
    PRME closed down 3.77 percent on Wednesday, May 8, 2024, on approximately normal volume.
    Earnings due: May 9
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical PRME trend table...
    Date Alert Name Type % Chg
    New Downtrend Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    NR7 Range Contraction -3.77%
    NR7-2 Range Contraction -3.77%
    Wide Bands Range Expansion -3.77%
    NR7 Range Contraction -0.74%
    Wide Bands Range Expansion -0.74%
    New Uptrend Bullish -4.11%
    Wide Bands Range Expansion -4.11%
    Gapped Up Strength -4.11%
    Older End-of-Day Signals for PRME ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 16 hours ago
    Fell Below Previous Day's Low about 17 hours ago
    60 Minute Opening Range Breakdown about 18 hours ago
    Down 5% about 18 hours ago
    Down 3% about 21 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    PRME Chart by TradingView
    Basic chart:

    Profile

    Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Disease Emerging Technologies Molecular Biology Medical Genetics Genetic Engineering Gene Editing Gene Editing Technology

    Is PRME a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
    May 3 What Makes Prime Medicine, Inc. (PRME) a New Buy Stock
    May 2 Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
    May 1 Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
    Apr 30 Prime Medicine gets green light for trials of first-ever prime editing drug
    Apr 29 FDA clears Prime Medicine to begin gene therapy clinical testing
    Apr 29 Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Apr 29 Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
    Apr 29 Prime gets FDA green light to begin first trial test of ‘prime editing’
    Apr 29 Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
    See more PRME news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.195
    52 Week Low 4.11
    Average Volume 711,882
    200-Day Moving Average 8.48
    50-Day Moving Average 6.39
    20-Day Moving Average 5.09
    10-Day Moving Average 5.13
    Average True Range 0.48
    RSI (14) 47.09
    ADX 25.96
    +DI 22.79
    -DI 23.44
    Chandelier Exit (Long, 3 ATRs) 4.96
    Chandelier Exit (Short, 3 ATRs) 5.55
    Upper Bollinger Bands 6.00
    Lower Bollinger Band 4.18
    Percent B (%b) 0.65
    BandWidth 35.67
    MACD Line -0.23
    MACD Signal Line -0.39
    MACD Histogram 0.1659
    Fundamentals Value
    Market Cap 521.66 Million
    Num Shares 97.3 Million
    EPS -1.78
    Price-to-Earnings (P/E) Ratio -3.01
    Price-to-Sales 0.00
    Price-to-Book 3.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.89
    Resistance 3 (R3) 5.88 5.70 5.80
    Resistance 2 (R2) 5.70 5.57 5.70 5.77
    Resistance 1 (R1) 5.53 5.48 5.44 5.54 5.74
    Pivot Point 5.35 5.35 5.31 5.35 5.35
    Support 1 (S1) 5.18 5.22 5.09 5.19 4.98
    Support 2 (S2) 5.00 5.13 5.00 4.95
    Support 3 (S3) 4.83 5.00 4.92
    Support 4 (S4) 4.84